201 related articles for article (PubMed ID: 26162688)
1. Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.
Hedrick E; Crose L; Linardic CM; Safe S
Mol Cancer Ther; 2015 Sep; 14(9):2143-53. PubMed ID: 26162688
[TBL] [Abstract][Full Text] [Related]
2. Reactive Oxygen Species (ROS)-Inducing Triterpenoid Inhibits Rhabdomyosarcoma Cell and Tumor Growth through Targeting Sp Transcription Factors.
Kasiappan R; Jutooru I; Mohankumar K; Karki K; Lacey A; Safe S
Mol Cancer Res; 2019 Mar; 17(3):794-805. PubMed ID: 30610105
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of phenethylisothiocyanate and other reactive oxygen species-inducing anticancer agents.
Jutooru I; Guthrie AS; Chadalapaka G; Pathi S; Kim K; Burghardt R; Jin UH; Safe S
Mol Cell Biol; 2014 Jul; 34(13):2382-95. PubMed ID: 24732804
[TBL] [Abstract][Full Text] [Related]
4. Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs.
Gandhy SU; Kim K; Larsen L; Rosengren RJ; Safe S
BMC Cancer; 2012 Nov; 12():564. PubMed ID: 23194063
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
Chadalapaka G; Jutooru I; Sreevalsan S; Pathi S; Kim K; Chen C; Crose L; Linardic C; Safe S
Int J Cancer; 2013 Feb; 132(4):795-806. PubMed ID: 22815231
[TBL] [Abstract][Full Text] [Related]
6. Piperlongumine Induces Reactive Oxygen Species (ROS)-Dependent Downregulation of Specificity Protein Transcription Factors.
Karki K; Hedrick E; Kasiappan R; Jin UH; Safe S
Cancer Prev Res (Phila); 2017 Aug; 10(8):467-477. PubMed ID: 28673967
[TBL] [Abstract][Full Text] [Related]
7. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells.
Tomoyasu C; Kikuchi K; Kaneda D; Yagyu S; Miyachi M; Tsuchiya K; Iehara T; Sakai T; Hosoi H
Oncol Rep; 2019 Jan; 41(1):643-649. PubMed ID: 30365145
[TBL] [Abstract][Full Text] [Related]
8. GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway.
Pathi SS; Jutooru I; Chadalapaka G; Sreevalsan S; Anand S; Thatcher GR; Safe S
Mol Cancer Res; 2011 Feb; 9(2):195-202. PubMed ID: 21156786
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
[TBL] [Abstract][Full Text] [Related]
10. Combination of quercetin and hyperoside has anticancer effects on renal cancer cells through inhibition of oncogenic microRNA-27a.
Li W; Liu M; Xu YF; Feng Y; Che JP; Wang GC; Zheng JH
Oncol Rep; 2014 Jan; 31(1):117-24. PubMed ID: 24173369
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
Heinicke U; Fulda S
Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
[TBL] [Abstract][Full Text] [Related]
12. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors.
Chintharlapalli S; Papineni S; Lei P; Pathi S; Safe S
BMC Cancer; 2011 Aug; 11():371. PubMed ID: 21864401
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells.
Pathi SS; Lei P; Sreevalsan S; Chadalapaka G; Jutooru I; Safe S
Nutr Cancer; 2011; 63(7):1133-42. PubMed ID: 21919647
[TBL] [Abstract][Full Text] [Related]
14. Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells.
Beccafico S; Morozzi G; Marchetti MC; Riccardi C; Sidoni A; Donato R; Sorci G
Carcinogenesis; 2015 Sep; 36(9):1071-83. PubMed ID: 26153023
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent.
Shen J; Hong Y; Zhao Q; Zhang JL
Tumour Biol; 2016 Jan; 37(1):1025-33. PubMed ID: 26269112
[TBL] [Abstract][Full Text] [Related]
16. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Haydn T; Metzger E; Schuele R; Fulda S
Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
[TBL] [Abstract][Full Text] [Related]
17. Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines.
Marampon F; Di Nisio V; Pietrantoni I; Petragnano F; Fasciani I; Scicchitano BM; Ciccarelli C; Gravina GL; Festuccia C; Del Fattore A; Tombolini M; De Felice F; Musio D; Cecconi S; Tini P; Maddalo M; Codenotti S; Fanzani A; Polimeni A; Maggio R; Tombolini V
Cancer Lett; 2019 Oct; 461():90-101. PubMed ID: 31325529
[TBL] [Abstract][Full Text] [Related]
18. The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells.
Laszig S; Boedicker C; Weiser T; Knapp S; Fulda S
Cancer Lett; 2020 Aug; 486():46-57. PubMed ID: 32445837
[TBL] [Abstract][Full Text] [Related]
19. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells.
Enßle JC; Boedicker C; Wanior M; Vogler M; Knapp S; Fulda S
Cancer Lett; 2018 Aug; 428():160-172. PubMed ID: 29709701
[TBL] [Abstract][Full Text] [Related]
20. Specificity Proteins (Sp) and Cancer.
Safe S
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]